Erman Akkus: TACE plus+ treatments in Hepato-Cellular Carcinoma
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:
“TACE plus+ treatments in Hepato-Cellular Carcinoma. Two recent trials at The Lancet.
EMERALD-1
- TACE-durva-beva vs. TACE
- PFS: 15 vs 8.2 months, HR:0·77 (95% CI 0·61–0·98), p=0·032
- TACE-durva vs. TACE:
- PFS: 10 vs 8.2 months
LEAP-012
- TACE-pembro-lenva vs. TACE
- PFS: 14.6 vs. 10 months, HR: 0·66 (95% CI 0·51–0·8); one-sided p=0·0002
TACE plus beva alone?
TACE-atezo-beva, pilot study, NCT05776875″
Authors: Bruno Sangro, Masatoshi Kudo, Joseph P Erinjeri, Shukui Qin, Zhenggang Ren, Stephen L Chan, Yasuaki Arai, Jeong Heo, Anh Mai, Jose Escobar, Yamil Alonso Lopez Chuken, Jung-Hwan Yoon, Won Young Tak, Valeriy V Breder, Tanita Suttichaimongkol, Mohamed Bouattour, Shi-Ming Lin, Jean-Marie Peron, Quang T Nguyen, Lunan Yan, Chang-Fang Chiu, Florinda A Santos, Anil Veluvolu, Satheesh Chiradoni Thungappa, Marco Matos, Magdalena Żotkiewicz, Stephanie I Udoye, John F Kurland, Gordon J Cohen and Riccardo Lencioni
Authors: Masatoshi Kudo, Zhenggang Ren, Yabing Guo, Guohong Han, Hailan Lin, Jinfang Zheng, Sadahisa Ogasawara, Ji Hoon Kim, Haitao Zhao, Chuan Li, David C Madoff, R Mark Ghobrial, Tomokazu Kawaoka, René Gerolami, Masafumi Ikeda, Hiromitsu Kumada, Anthony B El-Khoueiry, Arndt Vogel, Xiang Peng, Kalgi Mody, Corina Dutcus, Leonid Dubrovsky, Abby B Siegel, Richard S Finn and Josep M Llovet
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
More posts featuring Erman Akkus.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023